Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - CytomX Therapeutics, Inc. | ctmx-ex321_13.htm |
EX-31.2 - EX-31.2 - CytomX Therapeutics, Inc. | ctmx-ex312_7.htm |
EX-31.1 - EX-31.1 - CytomX Therapeutics, Inc. | ctmx-ex311_9.htm |
EX-23.1 - EX-23.1 - CytomX Therapeutics, Inc. | ctmx-ex231_11.htm |
10-K - 10-K - CytomX Therapeutics, Inc. | ctmx-10k_20171231.htm |
Exhibit 23.2
CONSENT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-214418 and 333-216567) and Form S-8 (Nos. 333-207694, 333-209992 and 333-215795) of CytomX Therapeutics, Inc. of our report dated March 2, 2017 relating to the financial statements, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
San Jose, California
March 7, 2018